{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:13:54Z","timestamp":1787670834820,"version":"build-2736575974"},"reference-count":22,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T00:00:00Z","timestamp":1649894400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis caused by the expression of CD68-positive and CD1a-negative foam tissue cells, which is polar in pediatric patients. The study reports a case of an 8-year-old Chinese boy who presented with polydipsia and polyuria for 4 years, followed by central nervous system symptoms. Magnetic resonance imaging (MRI) showed a large lesion in the lateral ventricle. The histiocytes stained positively for CD68, CD163 and negatively for CD1a, glial fibrillary acidic protein (GFAP) and langerin, and were partially positive for S100 by immunohistochemical assay. More importantly, BRAFV<jats:italic><jats:sup>600E<\/jats:sup><\/jats:italic> staining was positive in tissue, and the BRAF<jats:italic><jats:sup>V600E<\/jats:sup><\/jats:italic> mutations was also detected by real-time quantitative PCR (RT-qPCR) in the intracranial lesion tissue. According to our review of the literature, this is a rare case of ECD in the ventricle, with a younger age.<\/jats:p>","DOI":"10.3389\/fonc.2022.835076","type":"journal-article","created":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:48:02Z","timestamp":1649936882000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Paediatric Erdheim-Chester Disease in the Lateral Ventricle: A Case Report and Review of the Literature"],"prefix":"10.3389","volume":"12","author":[{"given":"Yimei","family":"Ma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi","family":"Wan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanmin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0b013e32834d861d","article-title":"Erdheim-Chester Disease","volume":"24","author":"Haroche","year":"2012","journal-title":"Curr Opin Rheumatol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-8-137","article-title":"Erdheim-Chester Disease: A Comprehensive Review of the Literature","volume":"8","author":"Mazor","year":"2013","journal-title":"Orphanet J Rare Dis"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.mayocp.2019.02.023","article-title":"The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease","volume":"94","author":"Goyal","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa008","article-title":"Neurologic and Oncologic Features of Erdheim-Chester Disease: A 30-Patient Series","volume":"22","author":"Bhatia","year":"2020","journal-title":"Neuro Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2015.03.004","article-title":"Erdheim-Chester Disease","volume":"26","author":"Campochiaro","year":"2015","journal-title":"Eur J Intern Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.03.004","article-title":"Cardiac Tamponade as the First Manifestation of Erdheim-Chester Disease","volume":"2","author":"Costa","year":"2020","journal-title":"Jacc-Cardiooncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2020.08.007","article-title":"Highlights of the Management of Adult Histiocytic Disorders: Langerhans Cell Histiocytosis, Erdheim-Chester Disease, Rosai-Dorfman Disease, and Hemophagocytic Lymphohistiocytosis","volume":"21","author":"Salama","year":"2021","journal-title":"Cl Lymph Myelom Leuk"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2016001784","article-title":"The Clinical Spectrum of Erdheim-Chester Disease: An Observational Cohort Study","volume":"1","author":"Estrada-Veras","year":"2017","journal-title":"Blood Adv"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019002766","article-title":"Erdheim-Chester Disease","volume":"135","author":"Haroche","year":"2020","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1002\/acn3.51014","article-title":"Neurological Manifestations of Erdheim-Chester Disease","volume":"7","author":"Boyd","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25055","article-title":"Phenotypes and Survival in Erdheim-Chester Disease: Results From a 165-Patient Cohort","volume":"93","author":"Cohen-Aubart","year":"2018","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-006-0160-9","article-title":"Neurological Manifestations and Neuroradiological Presentation of Erdheim-Chester Disease: Report of 6 Cases and Systematic Review of the Literature","volume":"253","author":"Lachenal","year":"2006","journal-title":"J Neurol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.11604\/pamj.2019.33.293.19194","article-title":"Erdheim-Chester Disease Revealed by Diabetes Insipidus","volume":"33","author":"Amor","year":"2019","journal-title":"Pan Afr Med J"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15306","article-title":"Paediatric Erdheim-Chester Disease With Aggressive Skin Manifestations","volume":"178","author":"Su","year":"2018","journal-title":"Br J Dermatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-020-04627-z","article-title":"Clinical Presentation, Imaging and Response to Interferon-Alpha Therapy in Erdheim-Chester Disease: Case-Based Review","volume":"40","author":"Iaremenko","year":"2020","journal-title":"Rheumatol Int"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/modpathol.2017.160","article-title":"The Histopathology of Erdheim-Chester Disease: A Comprehensive Review of a Molecularly Characterized Cohort","volume":"31","author":"Ozkaya","year":"2018","journal-title":"Mod Pathol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-04-570937","article-title":"Recurrent RAS and PIK3CA Mutations in Erdheim-Chester Disease","volume":"124","author":"Emile","year":"2014","journal-title":"Blood"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-03-771873","article-title":"Targeted Therapies in 54 Patients With Erdheim-Chester Disease, Including Follow-Up After Interruption (the LOVE Study)","volume":"130","author":"Cohen Aubart","year":"2017","journal-title":"Blood"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-019-1012-y","article-title":"Efficacy of MEK Inhibition in Patients With Histiocytic Neoplasms","volume":"567","author":"Diamond","year":"2019","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212678","article-title":"Efficacy of Infliximab in the Treatment of Erdheim-Chester Disease","volume":"77","author":"Cohen-Aubart","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2018.1450712","article-title":"Superior Efficacy and Similar Safety of Double Dose Anakinra in Erdheim-Chester Disease After Single Dose Treatment","volume":"7","author":"Franconieri","year":"2018","journal-title":"Oncoimmunology"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2017.1318237","article-title":"Tocilizumab in Patients With Multisystem Erdheim-Chester Disease","volume":"6","author":"Berti","year":"2017","journal-title":"Oncoimmunology"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.835076\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,14]],"date-time":"2022-04-14T11:48:04Z","timestamp":1649936884000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2022.835076\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,14]]},"references-count":22,"alternative-id":["10.3389\/fonc.2022.835076"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2022.835076","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,14]]},"article-number":"835076"}}